TARGETING INFLAMMATION AND ALLOIMMUNITY IN LUNG
TRANSPLANT RECIPIENTS WITH TOCILIZUMAB (ALL IN LUNG)
- Registry ID
- CTOT-45
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- NATIONAL INSTITUTES OF HEALTH
- Start date
- 2024-12-26
- Completion date
- 2025-07-21
- Last update
- 2024-03-22
Conditions
- LUNG TRANSPLANT RECIPIENT
Related clinical trials
- A PHASE 2B, NON-RANDOMIZED, CONTROLLED, OPEN-LABEL, EXTENSION STUDY TO EVALUATE
THE PERSISTENCE OF IMMUNE RESPONSE OF THE ADJUVANTED RSVPREF3 VACCINE AND THE
SAFETY AND IMMUNOGENICITY FOLLOWING REVACCINATION IN LUNG AND KIDNEY TRANSPLANT
RECIPIENTS (¿18 YEARS OF AGE)
- BELUMOSUDIL TO BLOCK CLAD IN HIGH RISK LUNG TRANSPLANT
RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE BLIND,
PLACEBO-CONTROLLED TRIAL
- SAFETY AND IMMUNOGENICITY OF NON-LIVE, ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS
(RSV) VACCINE IN ALLOGENEIC STEM CELL TRANSPLANT AND LUNG TRANSPLANT
RECIPIENTS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 STUDY, FOLLOWED BY OPEN-LABEL EXTENSIONS, TO EVALUATE THE EFFICACY OF ORAL BELUMOSUDIL IN ADULT PARTICIPANTS WITH CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) FOLLOWING BILATERAL LUNG TRANSPLANTATION
- A PHASE 2B, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO
EVALUATE THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN
ADULTS (¿50 YEARS OF AGE) WHEN ADMINISTERED TO LUNG AND RENAL TRANSPLANT RECIPIENTS
COMPARING 1 VERSUS 2 DOSES AND COMPARED TO HEALTHY CONTROLS (¿50 YEARS OF AGE)
RECEIVING 1 DOSE
View on source registry